Compare TXG & ZYME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TXG | ZYME |
|---|---|---|
| Founded | 2012 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Laboratory Analytical Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 1.9B |
| IPO Year | 2019 | 2022 |
| Metric | TXG | ZYME |
|---|---|---|
| Price | $21.69 | $26.76 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 15 | 11 |
| Target Price | $20.25 | ★ $38.90 |
| AVG Volume (30 Days) | ★ 2.4M | 517.9K |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 76.97 | 33.33 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $245,893,000.00 | $105,965,000.00 |
| Revenue This Year | N/A | $183.10 |
| Revenue Next Year | $7.33 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 68.06 | 38.87 |
| 52 Week Low | $7.72 | $10.89 |
| 52 Week High | $26.45 | $29.75 |
| Indicator | TXG | ZYME |
|---|---|---|
| Relative Strength Index (RSI) | 47.90 | 49.47 |
| Support Level | $11.66 | $22.28 |
| Resistance Level | $23.43 | $27.35 |
| Average True Range (ATR) | 1.42 | 1.03 |
| MACD | -0.32 | -0.23 |
| Stochastic Oscillator | 31.02 | 11.52 |
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The company's integrated solutions include instruments, consumables, and software for analyzing biological systems at a resolution and scale that matches the complexity of biology. Its product offerings include a Chromium platform comprising microfluidic chips and related consumables, Chromium X series, Visium and Xenium platforms, and others, which are predominantly used for the study of biological components. Geographically, the company derives operates from the United States and the rest from Americas (excluding the United States), Europe, Middle East and Africa, China, and Asia-Pacific (excluding China).
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. It is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.